ECSP11010901A - Compuestos de amida útiles en terapia - Google Patents

Compuestos de amida útiles en terapia

Info

Publication number
ECSP11010901A
ECSP11010901A EC2011010901A ECSP11010901A ECSP11010901A EC SP11010901 A ECSP11010901 A EC SP11010901A EC 2011010901 A EC2011010901 A EC 2011010901A EC SP11010901 A ECSP11010901 A EC SP11010901A EC SP11010901 A ECSP11010901 A EC SP11010901A
Authority
EC
Ecuador
Prior art keywords
optionally substituted
substituents
alkyl
independently selected
oxo
Prior art date
Application number
EC2011010901A
Other languages
English (en)
Inventor
Florian Wakenhut
Toby James Underwood
Kart Richard Gibson
Martin Peter Green
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of ECSP11010901A publication Critical patent/ECSP11010901A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Un compuesto de Fórmula (I), o una sal o solvato farmacéuticamente aceptable del mismo, ( consta diseño) en la que, cada uno de R1 y R2 representa independientemente H, halógeno, CF3, alquilo C1-3 o alcoxi C1-3; R3 representa alquilo C1-6, cicloalquilo C3-6, fenilo (opcionalmente sustituido con uno o más sustituyentes, cada uno seleccionado independientemente entre Ra) o Het (opcionalmente sustituido con uno o más sustituyentes, cada uno seleccionado independientemente entre OH, oxo o alquilo C1-4);R4 representa H o alquilo C1-3; R5 representa alquilo C1-6 (opcionalmente sustituido con uno o más sustituyentes, cada uno seleccionado independientemente entre Rb), cicloalquilo C3-6 (opcionalmente sustituido con uno o más sustituyentes, cada uno seleccionado independientemente entre oxo o OH) o Het2 (opcionalmente sustituido con uno o más sustituyentes, cada uno seleccionado independientemente entre Rd); átomo de oxígeno o 1 átomo de azufre, o (c) 1 átomo de oxígeno o 1 átomo de azufre, (opcionalmente sustituido con uno o más sustituyentes, cada uno seleccionado independientemente entre OH, oxo o alquilo C1-4); y R6 representa alquilo C1-3 (opcionalmente sustituido con uno o más sustituyentes, cada uno seleccionado independientemente entre Rf), cicloalquilo C3-5 (opcionalmente sustituido con uno o más halógenos), CN o halógeno; en los que Rf representa halógeno o fenilo:y composiciones, procedimientos para la preparación y usos del mismo, por ejemplo en el tratamiento de endometriosis o fibromiosis uterina.
EC2011010901A 2008-09-18 2011-03-17 Compuestos de amida útiles en terapia ECSP11010901A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9790208P 2008-09-18 2008-09-18

Publications (1)

Publication Number Publication Date
ECSP11010901A true ECSP11010901A (es) 2011-04-29

Family

ID=41269630

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010901A ECSP11010901A (es) 2008-09-18 2011-03-17 Compuestos de amida útiles en terapia

Country Status (20)

Country Link
US (2) US8232269B2 (es)
EP (1) EP2350017A1 (es)
JP (1) JP2012502975A (es)
KR (1) KR20110044304A (es)
CN (1) CN102159548A (es)
AP (1) AP2011005611A0 (es)
AU (1) AU2009294290B2 (es)
BR (1) BRPI0918935A2 (es)
CA (1) CA2735931A1 (es)
CL (1) CL2011000570A1 (es)
CO (1) CO6351734A2 (es)
DO (1) DOP2011000083A (es)
EA (1) EA201100368A1 (es)
EC (1) ECSP11010901A (es)
IL (1) IL211479A0 (es)
MA (1) MA32642B1 (es)
MX (1) MX2011002899A (es)
PE (1) PE20110793A1 (es)
WO (1) WO2010032200A1 (es)
ZA (1) ZA201102690B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2541295T3 (es) * 2011-04-21 2015-07-17 Orion Corporation Carboxamidas que modulan el receptor de andrógenos
US9370521B2 (en) * 2011-07-21 2016-06-21 The Regents Of The University Of California Targeting GLI proteins in human cancer by small molecules
RU2617696C2 (ru) 2012-02-17 2017-04-26 ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО., ЛТД Способы и соединения, которые можно использовать для синтеза антагонистов рецепторов орексина-2
EP2700635A1 (en) 2012-08-20 2014-02-26 Basf Se 5-Trifluoromethylpyrazole amides having herbicidal activity
JP2016505049A (ja) 2013-01-23 2016-02-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 小分子によるヒト癌におけるｇｌｉタンパク質のターゲティング方法
DK2958921T3 (da) 2013-02-22 2017-11-06 Pfizer Pyrrolo[2,3-D]pyrimidin-derivater som hæmmere af Janus kinaser (JAK)
WO2014143617A1 (en) * 2013-03-14 2014-09-18 Teva Women's Health, Inc. Deuterium-enriched tanaproget and processes for its preparation
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US20190321363A1 (en) * 2016-06-20 2019-10-24 Dr. Reddy's Laboratories Limited Process for the preparation of elagolix sodium and its polymorph
CN108623446A (zh) * 2017-03-24 2018-10-09 北京艾德旺科技发展有限公司 一种合成3，3-二氟环丁烷甲酸的方法
AU2020373913B2 (en) * 2019-10-28 2024-04-18 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof
WO2023217203A2 (zh) * 2022-05-12 2023-11-16 西北农林科技大学 二苯基吡唑类化合物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604218A1 (en) * 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
CN101282936B (zh) * 2005-10-07 2012-05-16 橘生药品工业株式会社 氮化杂环化合物及包含其的药物组合物

Also Published As

Publication number Publication date
BRPI0918935A2 (pt) 2015-12-01
US20120316150A1 (en) 2012-12-13
PE20110793A1 (es) 2011-10-31
EA201100368A1 (ru) 2011-12-30
US8232269B2 (en) 2012-07-31
CL2011000570A1 (es) 2011-06-17
JP2012502975A (ja) 2012-02-02
MX2011002899A (es) 2011-04-11
AU2009294290A1 (en) 2010-03-25
KR20110044304A (ko) 2011-04-28
WO2010032200A1 (en) 2010-03-25
AU2009294290B2 (en) 2012-08-30
MA32642B1 (fr) 2011-09-01
DOP2011000083A (es) 2011-03-31
EP2350017A1 (en) 2011-08-03
CA2735931A1 (en) 2010-03-25
US20100249091A1 (en) 2010-09-30
ZA201102690B (en) 2011-12-28
AP2011005611A0 (en) 2011-04-30
IL211479A0 (en) 2011-05-31
CN102159548A (zh) 2011-08-17
CO6351734A2 (es) 2011-12-20

Similar Documents

Publication Publication Date Title
ECSP11010901A (es) Compuestos de amida útiles en terapia
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR094452A1 (es) COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
AR080841A1 (es) Derivados de isoxazolina sustituida; composiciones veterinarias que los comprenden y su uso en el tratamiento de parasitos en animales
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR082201A1 (es) Bencenosulfonamidas utiles como inhibidores del canal de sodio
AR061923A1 (es) Compuestos derivados de benzofuran-piperidina
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
AR082153A1 (es) N-sulfonilbenzamidas utiles como inhibidor del canal de sodio
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR086958A1 (es) Antagonistas de trpv4
AR089814A1 (es) Compuestos que modulan la actividad de los proteasomas
AR092288A1 (es) Ligandos del receptor ep1
AR101528A1 (es) Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
AR089815A1 (es) Compuestos que mejoran la actividad de los proteasomas
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
AR065872A1 (es) Derivados de benzimidazol sustituidos con heterociclos,composiciones farmaceuticas que los contienen,proceso para prepararlos y sus usos en trastornos de ansiedad, trastornos depresivos y enfermedades de alzheimer, entre otros.